semaglutide 1.34 just got FDA-approved for kidney disease. This changes everything., January 2025. The FDA approved semaglutide (Ozempic/Wegovy) for a new indication: reducing kidney disease progression in Ozempic 2 mg/1.5 mL (1.34

The approval of semaglutide marked a significant advancement in the pharmacological approach to managing obesity and diabetes, two of the most pressing public health concerns of our time

Acknowledging small wins, such as preparing balanced meals or keeping a consistent sleep routine, builds confidence that you can maintain progress on your own

It is added to sports supplements due to its rapid absorption rate, making it most suitable for additive in pre-workout and post-workout supplements

According to the FDA Adverse Events Reporting System (FAERS) Public Dashboard, there were 731 reports of pancreatitis and 39 reports of necrotizing pancreatitis from 2018 through 2024

10.1016/j.plaphy.2009.03.015 168 TakahashiM.TeradaY.NakaiI.NakanishiH.YoshimuraE.MoriS.et al